The tempting answer is to call this administrative inefficiency. Some of it is. But a larger part is institutional dependence. Schools have become the local delivery system for needs that cross education, health care, disability services, mental health, transportation, and family support. Then the financing arrives in fragments.
A child does not arrive at school in fragments.
The Statehouse should be careful here. It is easy to say districts must maximize Medicaid billing. It is easy to say they must document why another revenue source was unavailable. It is harder to ask whether a small district has the staff, software, legal comfort, and clinical coding capacity to do that without taking time away from education itself.
Special education is one of those subjects where everyone supports the principle until the bill is due. The bill is now due every year.
COVID Oversight and the Problem of Knowing
The COVID Response Efficacy committee is the most volatile of the three subjects because it sits at the intersection of grief, distrust, science, and politics.
There is nothing wrong with reviewing a state’s pandemic response. There is nothing wrong with asking whether public-health agencies were transparent enough, whether emergency powers were used wisely, whether school closures did lasting harm, or whether vaccine recommendations were communicated with enough humility about uncertainty. Those are legitimate questions. Some of them should have been asked earlier and better.
The danger comes when oversight becomes a verdict in search of evidence.
The committee’s June discussions focused heavily on vaccine safety, federal data transparency, and claims about adverse events. The federal debate has also shifted. The U.S. Senate Permanent Subcommittee on Investigations, chaired by Senator Ron Johnson, held hearings in 2026 alleging that Biden-era health officials ignored or downplayed COVID-19 vaccine safety signals.⁶ At the same time, federal health agencies continue to recommend the 2025-26 COVID-19 vaccine for people six months and older through individual-based decision-making, with risk-benefit considerations varying by age and health status.⁷
Both facts can be true. Vaccine safety systems can deserve scrutiny, and a vaccine can still have a favorable risk-benefit profile for many people. Myocarditis after mRNA vaccination is a real safety issue, particularly in young males, and federal labeling has been updated to reflect that risk.⁸ But a real signal is not a license to treat every alarming claim as established fact.
That distinction is where public trust either begins to recover or collapses further.
A Legislature is not a medical journal. It should not pretend to be one. But it also should not outsource judgment entirely to federal agencies, especially after a pandemic in which public officials often spoke with more certainty than the evidence warranted. The useful role for a state committee is not to perform science by anecdote. It is to ask whether institutions had the right systems, whether data were available, whether dissenting evidence was evaluated fairly, and whether public guidance was honest about tradeoffs.
That is oversight.